| C |
|
C4b-binding Protein (C4BP) Prolongs the Survival of Human Protein S in an Experimental Mouse Model
|
| Lenting PJ, Roberts SJ, Gomes L, Hackeng TM, Denis CV |
| |
|
C4b-binding Protein and the Risk of Venous Thrombosis
|
| Meijers JCM, Lisman T, de Groot PhG, Rosendaal FR |
| |
|
C677T and A1298C MTHFR, A2756G MTR and 844ins68 CBS Gene Polymorphisms in Atrial Fibrillation
|
| Giusti B, Gensini F, Sestini I, Lenti M, Saracini C, Falciani M, Innocenti D, Pepe G, Abbate R, Gensini GF |
| |
|
Calcineurin and Protein Kinase C Reciprocally Regulate PAR-1 – Dependent Ca2+ Release In Human Platelets
|
| Harper MT, Sage SO |
| |
|
Calcium Mobilization Required for Firm Platelet Attachment is Dependent upon Both ADP and Thromboxane A2 during Thrombus Formation in a Living Mouse
|
| Dubois C, Panicot-Dubois L, Furie BC, Furie B |
| |
|
Calculation of the Direct INR Calibration Line Using Linear and Orthogonal Regression
|
| Johnston M, Lauzon M, Angeloni F |
| |
|
CalDAG-GEFI and Protein Kinase C (PKC) Represent Alternative Pathways Leading to Activation of Integrin aIIbb3 in Platelets
|
| Bergmeier W, Crittenden JR, Piffath CL, Polgar J, Housman DE, Graybiel AM, Wagner DD |
| |
|
Can the Rotem® Predict Post-Operative Bleeding and Appropriate Treatment after Cardiac Surgery?
|
| Davidson SJ, McGrowder D, Burman JF, Kelleher AA |
| |
|
Cancer Procoagulant Enhances Tumor Cell Adhesion to the Extracellular Matrix
|
| Kamocka M, Wolter W, Pollard M, Suckow M, Rozalski M, Krajewska U, Kaplinska K, Mielicki WP, Rosen ED |
| |
|
Carbohydrate-Based P-Selectin Antagonists: In vitro- and In Vivo Investigations of Structure-Activity Relationships
|
| Alban S, Fritzsche J, Ludwig RJ, Schumacher G, Boehncke WH, Bendas G |
| |
|
Cardiac Involvement in Pathologic Findings of Factor XIII Knockout Mice
|
| Souri M, Kuno-Koseki S, Takeda N, Yamakawa M, Degen JL, Ichinose A |
| |
|
Cardiac Myocytes and Cardiac Fibroblasts Are Actively Involved in the Recruitment of Monocytes
|
| Hohensinner PJ, Kaun C, Demyanets S, Maurer G, Huber K, Wojta J |
| |
|
Cardiomyogenic Differentiation Induced by in vitro Manipulation of Adult Stem Cells
|
| Burlacu A, Maniu H, Rosca A-M, Fleseriu I, Jinga V, Simionescu M |
| |
|
Cardioprotective Effect of KR-32568, a Novel Sodium/hydrogen Exchanger-1 Inhibitor, in a Rat Model of Ischemia and Reperfusion Heart Injury
|
| Roh HY, Jung IS, Park JW, Yun YP, Yi KY, Yoo SE, Kwon SH, Chung HJ, Shin HS |
| |
|
Cardiovascular Interventions and Surgery in Patients with Haemophilia and Von Willebrand Disease
|
| Steiner B, Burstein C, Ince H, Freund M |
| |
|
Cardiovascular Risk Factors and the Risk of Venous Thromboembolism
|
| Tufano A, Macarone PN, Cirillo F, Coppola A, Cimino E, Migliaresi P, Cerbone AM, Di MG |
| |
|
Cardiovascular Risk Factors Contributing to Endogenous Thrombin Potential (ETP) in Type 2 Diabetes
|
| Goodall AH, Hogwood J, Toh C-H, Mather H, Humphries SE, Esmon CT, Ireland H |
| |
|
Carotid Plaque and Hypercoagulability Are Strong Risk Factors for Ischemic Stroke
|
| Corinaldesi G, Corinaldesi C |
| |
|
Carrier Detection and Prenatal Diagnosis of Two Short Tandem Repeats within Factor VIII Gene in Iranian Population
|
| Rabbani B, Khan-Ahamad H, Rezaeian A, Sarrami R, Nafissi N, Amini-Bavil-Olyaee S, Karimipour M, Zeinali S |
| |
|
Carrier Detection and Prenatal Diagnosis on Hemophilia
|
| Wang X-f, Liu Y-f, Liu X-f, Chu H-l, Fang Y, Fan Q-s, Wang H-l |
| |
|
Carrier Testing of Hemophilia B by SSCP and Sequencing in One Iranian Family
|
| Nafissi N, Karimipoor M, Lak M, Rabbani B, Eram SM, Zeinali S |
| |
|
Case Report of Patient with Homozygous FXII deficiency, Heterozygous FXI deficiency and Antiphospholipid Antibodies
|
| Lawler P, Owens D, Jones DW, O'Connell N, Lee CA |
| |
|
Case Report on Successful Use of Activated Prothrombincomplex Concentrate FEIBA® in Orthopedic Surgery on Two Patients with Factor VIII Inhibitors
|
| Baghaei F, Boberg P, Wollter I, Stigendal L |
| |
|
Case Series of Acquired Factor VIII Inhibitors: Profile in the Australian Capital Territory and Review of Literature
|
| Talaulikar D, McDonald A, Pratt J, Prosser IW, D'Rozario J, Pidcock ME |
| |
|
Catastrophic Antiphospholipid Antibody Syndrome: Successful Treatment with Immunosuppresive Therapy and Plasmapheresis
|
| Zakarija A, Boggio L, Green D |
| |
|
Catastrophic Antiphospholipid Syndrome and Kikuchi-Fujimoto Disease: The First Case Reported
|
| de Larrañaga G, Cunto E, Remondino G, Olenchuk A, Noguera C, Narbaitz M, Forastiero R, Gomez N, Zala N, San Juan J |
| |
|
Catheter Directed Thrombolysis of Acute Iliofemoral Deep Venous Thrombosis Is Effective and Preserves Venous Valve Function. Results from a Prospective One-centre Study of 60 Cases
|
| J[emptyv]rgensen M, Just S, Bækgaard N, Panduro L, Sillesen H |
| |
|
Caveolin-1 Expression Regulates Cell Surface Exposure and Anticoagulant Function of Tissue Factor Pathway Inhibitor
|
| Lupu C, Hu X, Lupu F |
| |
|
CCAAT Enhancer Binding Proteins: Co-Regulators of Haemostasis and the Metabolic Syndrome?
|
| Carter AM, Bennett CE, Bostock JA, Cymbalista CM, Freeman MS, Futers TS, Riches K, Rolton DJ, Scarrott TJ, Grant PJ |
| |
|
CD40 and CD40 Ligand (CD40L) in Primary Hemostasis and Antibody-Mediated Platelet Activation
|
| Langer F, Ingersoll S, Amirkhosravi A, Meyer T, Siddiqui FA, Ahmad S, Walker JM, Amaya M, Desai H, Francis JL |
| |
|
Cell Death Induced by Fibrin-Degradation Products
|
| Guo Y, Hendrikson SB, Hernandez I, Kerschen EJ, Mosesson MW, Weiler H |
| |
|
Cell-Based Models of Haemostasis
|
| Monroe DM, Hoffman M, Roberts HR |
| |
|
Cell-derived Microparticles Contain Caspase 3 in Vitro and in Vivo
|
| Abid Hussein MN, Nieuwland R, Hau RCM, Evers LM, Meesters EW, Sturk A |
| |
|
Cellular Effects of Heparin-PF4 Antibodies and Its Relevance to the Pathogenesis of Heparin-Induced Thrombocytopenia
|
| Ahmad S, Amirkhosravi A, Walker JM, Desai H, Amaya A, Langer F, Francis JL |
| |
|
Cellular Immune Responses in Hemophilia. Why do Inhibitors Develop in Some but not All Hemophiliacs?
|
| White II, GC1,2,3 , Kempton CL, Grimsley A, Nielsen B, Roberts HR |
| |
|
Central Venous Catheters Related Thrombosis in Hematological Patients
|
| Chistolini A, Morano S, Pignoloni P, Torelli F, Murgi E, Rosa G, Mazzucconi M |
| |
|
Cerebral Sinovenous Thrombosis during L-Asparaginase Treatment
|
| Santoro N, Giordano P, Nigro A, Di Cuonzo F, Salvati A, Palma M, Maghenzani M, Carella A, De Mattia D |
| |
|
Cerebral Sinovenous Thrombosis in Children
|
| Gentilomo C, Drigo P, Laverda AM, Battistella PA, Franzoi M, Suppiej A, Gavasso S, Pagnan A, Simioni P |
| |
|
Cerebral Venous Sinus Thrombosis in a 12 year Old Boy with Transient Antiphospholipid Antibodies
|
| Weidenhammer A, Christensen K, Meister S, Spranger T, Auerswald G |
| |
|
Cerebral Venous Thrombosis: The Padua Experience
|
| Sartori MT, Zampieri P, Munari M, Ricchieri GL, Tonello S, Carollo C, Spiezia L |
| |
|
Changes in Concentration of Specific Forms of Activated Factor XII Are Observed Following Thrombolytic Therapy with Tenecteplase
|
| Pönitz V, Pritchard D, Grundt H, Polwart R, Nilsen DW |
| |
|
Changes in Fibrinolysis Activity after Angiotensin II Receptor Blockade in Patients Undergoing Renal Artery Angiography
|
| Dielis AWJH, Smid M, Spronk HMH, van Oerle R, Govers-Riemslag JWP, van der Voort D, Houben B, Hamulyák K, Kroon AA, de Leeuw PW, ten Cate H |
| |
|
Changes in Fibrinolysis as a Result of Leakage Through Clot
|
| Savushkin AV |
| |
|
Changes in Thrombogenic Markers but not Factor XIII in Left Atrium of Thai Patients with Mitral Stenosis
|
| Komanasin N, Kiatchoosakun S, Wongvipaporn C, Silaraks S, Suongto U, Mongolwongroj P, Tatsanavivat P |
| |
|
Changes of Coagulation after Single i.v. Bolus 0.75 mg Per kg of Low Molecular Weight Heparin Enoxaparin During PCI – A Pharmacokinetic Study
|
| Kvasni[ccaron]ka J, Horák J, Bílková J, Bumbal J, [Scaron]imek , Kovárník T, Malíková I, Kvasni[ccaron]ka T, Aschermann M |
| |
|
Changes of Factor VII Coagulant Activity in Oral Warfarin Patients
|
| Zeng SY, Zhang DW, Yu ZC |
| |
|
Changes of Tissue Factor Pathway in Patients with Hypertension and Coronary Heart Disease
|
| He XF, Wen ZB, Xiao ZJ, Li JC, He SL |
| |
|
Characterisation and Classification of Von Willebrand Diseases
|
| Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H |
| |
|
Characterisation If Species Differences in the Platelet Thrombin/ADP Response
|
| Nylander S, Mattsson C, Lindahl TL |
| |
|
Characterisation of Anti-ADAMTS13 Autoantibodies from a Patient with Thrombotic Thrombocytopenic Purpura (TTP)
|
| Crawley JTB, Mollica L, Preston RJS, Mackie I, Starke R, Machin S, Lane DA |
| |
|
Characterisation of the Anticoagulant Properties of a Phospholipase A2 from the Venom of the Australian King Brown Snake (Pseudechis australis)
|
| Snelling H, St Pierre L, Masci P, Lavin M |
| |
|
Characterisation of the Novel, High Purity, Double Virus Inactivated von Willebrand Factor and Factor VIII Concentrate Wilate
|
| Stadler M, Gruber G, Kannicht C, Biesert L, Radomski KU, Suhartono H, Pock K, Neisser-Svae1 , Weinberger J, Roemisch J, Svae TE |
| |
|
Characterization and Gene Silencing of a Novel Gla-Containing Protein
|
| Chu K, Schlachterman A, High KA |
| |
|
Characterization and Performance of the HemosIL Silica Clotting Time (SCT) Test for Detection of Lupus Anticoagulants
|
| Bottenus R, Cueto C, Triscott M |
| |
|
Characterization and Thrombogenicity of Microparticles Derived from Endothelial Cells, Smooth Muscle Cells, and Monocytes as Measured By a Novel Thrombin Generation Assay (TECHNOTHROMBIN® TGA)
|
| Isobe H, Kaufmann V, Mager J, Botchkov V, Binder BR |
| |
|
Characterization of a Novel Recombinant Factor VIIa Analog in a Cell-Based Model of Coagulation
|
| Allen G, Hoffman M, Persson E |
| |
|
Characterization of Anti-Human and Anti-Porcine Factor VIII Monoclonal Antibodies Produced by Hemophilia A Mice
|
| Lollar P, Barrow RT, Parker ET, Healey JF |
| |
|
Characterization of B-Domain Sequences on Factor V Which Influence the Procofactor to Cofactor Transition
|
| Camire RM, Zhu H |
| |
|
Characterization of ELISA's Exclusively Reacting with TAFI, the Released Activation Peptide from TAFI and Activated TAFI Using an in vitro Clot Lysis Assay
|
| Ceresa E, Declerck PJ, Gils A |
| |
|
Characterization Of Factor IX With Mutations At Residues 190 And 192 Of The Heavy Chain Of Defective Factor IX Found In Patients With Hemophilia B
|
| Lin C-n, Shi G-y, Wu H-l, Hamaguchi N, Shu-Wha Lin S-w |
| |
|
Characterization of Factor VIII Autoantibodies with Complex Reaction Kinetics is Improved by Heat Inactivation of the Test Plasma to Remove Residual Factor Activity
|
| Sahud M, Ruden S, Soriano C, Didon S |
| |
|
Characterization of Human Endothelial Progenitor Cells Under Various Flow Conditions
|
| Mazzolai L, Bouzourene K, Hayoz D, Dignat-George F, Liu JW, Bounameaux H, Kruithof EKO |
| |
|
Characterization of Recombinant Canine Factor VIII and Quantitative Determination of Factor VIII in Canine Plasma
|
| Shibata M, Rowle F, Labelle A, Andrews C, Hough C, Yoshioka A, Lillicrap D |
| |
|
Characterizing the Plasma Clot Proteome
|
| Howes J-M, Keen JN, Findlay JBC, Grant PJ, Carter AM |
| |
|
Chemically Distinct Anticoagulants Exert Differential Effects on Experimental Melanoma Metastasis
|
| Alban S, Ludwig RJ, Kaufmann R, Diehl S, Henschler R, Boehncke WH, Gille J |
| |
|
Childhood Acquired Hepatitis C Infection in Patients with Hemophilia: A Cohort Study
|
| Posthouwer D, Fischer K, van Erpecum KJ, Mauser-Bunschoten EP |
| |
|
Chimeric PAI-1-dsRed Fusion Protein Characterization and Expression in MEG-01 Megakaryocytic Cells: Model for PAI-1 Trafficking from a-Granules to Cell Surfaces
|
| Leong HS, Bateman RM, Walinski H, Podor TJ |
| |
|
Chromogenic and Clot Based Protein C Assays Contribute to the Management Of Homozygous Protein C Deficient Patients
|
| Monagle P, Ignjatovic V, Newall F, Savoia H, Campbell J, Barnes C, Hardikar W, Smith A |
| |
|
Chromogenic and Fluorogenic Thrombin Generation Assays in Factor XI Deficiency: Correlation with Bleeding Phenotype
|
| O’Connell NM, Riddell AF, Lee CA, Perry DJ |
| |
|
Ciclooxygenase-1 C50T Polymorphism Modulates the Thromboxane A2 Level and might Affect the Efficacy of Aspirin
|
| Rivera J, Gonzalez-Conejero R, Corral J, Guerrero JA, Martinez C, Lozano ML, Vicente V |
| |
|
Circadian Clock Genes are Involved in the Regulation of fibrinolytic Activities in Mice
|
| Ohkura N, Oishi K, Fukushima N, Kasamatsu M, Shirai H, Amagai N, Matsuda J, Ishida N, Horie S |
| |
|
Circadian Oscillation of Thrombomodulin Gene Expression in Peripheral Tissues
|
| Horie S, Oishi K, Ohkura N, Atsumi G, Sekine Y, Shirai H, Takeda N, Maemura K, Ishida N, Matsuda J |
| |
|
Circulating Endothelial Cell Count as a Diagnostic Marker for Non-ST Elevation Acute Coronary Syndromes
|
| Banzet N, Quilici J, Paule P, Meynard JB, Mutin M, Bonnet JL, Ambrosi P, Sampol J, Dignat-George F |
| |
|
Circulating Endothelial Cells in Acute Ischaemic Stroke
|
| Nadar SK, Lip GYH, Lee KW, Blann AD |
| |
|
Circulating Inflammatory Markers and Risks of Cardiovascular and Noncardiovascular Disease
|
| Lowe GDO |
| |
|
Circulating Inhibitor in an Elderly Female That Impairs the Action of Human But Not Rabbit Brain Thromboplastin
|
| Messmore HL, Adess M, Fabbrini N, Choudhury A, Bhoopalam N, Diaz M, Iqbal A, Balbale S, Love B, Zarr C, Schlimm S, Bird ML |
| |
|
Circulating oxLDL/b2GPI Complexes, Autoantibodies and Intima-media Thickness in Patients with Systemic Lupus Erythematosus: Possible Role in Autoimmune-mediated Atherosclerosis
|
| Lopez LR, Hurley BL, Simpson DF, Palafox-Sánchez C, Salazar-Páramo M, Matsuura E, García De La Torre I |
| |
|
Circulating Platelet-Derived Microparticles in Systemic Lupus Erythematosus: Association with Increased Thrombin Generation and Procoagulant State
|
| Alfaro G, Pereira J, Goycoolea M, Quiroga T, Ocqueteau M, Massardo L, Pérez C, Sáez CG, Mezzano D |
| |
|
Circulating Platelet-Monocyte Complexes Are Inversely Correlated with Serum Apo-A Levels
|
| Zouaoui Boudjeltia K, Cauchie P, Piro P, Kerkhofs M, Vanhaeverbeek M, Remacle C, Brohee D |
| |
|
Circulating Tissue Factor Activity Is Increased by Hyperglycemia and Hyperinsulinemia in Normal Human Subjects
|
| Vaidyula VR, Boden G, Mozzoli M, Cheung P, Rao AK |
| |
|
Clearance of Latent and Polymeric Antithrombin. Are These Conformational Variants Prothrombotic?
|
| Hernández-Espinosa D, Rivera J, Guerrero JA, Miñano A, Alberca I, Cano H, Lozano ML, López-Sánchez ML, Vicente V, Corral J |
| |
|
Clearance of Plasminogen Activator Inhibitor-1 in Low-Density Lipoprotein Receptor-Related Protein Deficient Mice
|
| Hu L, van Vlijmen BJM, Bovenschen N, Huisman MV, Meinders AE, Havekes LM, Tamsma JT |
| |
|
Clearance of Procoagulant Platelet-Derived Microparticles from the Circulation of Rabbits
|
| Rand ML, Wang H, Bang KWA, Packham MA, Freedman J |
| |
|
Cleavage of Ultra-large von Willebrand Factor by ADAMTS-13 Under Flow Conditions
|
| Dong JF |
| |
|
Clinical ‘Aspirin Resistance’ Is Associated with Increased Cyclooxygenase-Independent Platelet Activation
|
| Frelinger AL, Linden MD, Furman MI, Li Y, Fox ML, Barnard MR, Michelson AD |
| |
|
Clinical and Laboratory Diagnosis of Heparin Induced Thrombocytopenia (HIT)
|
| Patel RK, Yallop D, Ford E, Thumpston J, Arya R |
| |
|
Clinical and Laboratory Features of Mild Bleeding Disorders (MBD) in Children
|
| Brandão LR, Briones M, Miller CH, White JG, Kauffman J, Abshire TC |
| |
|
Clinical and Laboratory Predictors of Recurrent Venous Thrombosis: Interim Results from a Multi-center Prospective Observational Study
|
| Tait RC, Lowe GDO, McColl MD, McMahon AD, Robertson L, King L, Clarke S, Conkie J, Roditi GH, Walker ID |
| |
|
Clinical and Laboratory Response to rFVIIa and APCC in a Rare Case of Severe Congenital Factor VII Deficiency with an Inhibitor
|
| St-Louis J, Boulanger A, Meilleur C, Lacroix S, Rivard GE |
| |
|
Clinical and Laboratory Risk Factors in a Group of Patients with Venous Thromboembolism
|
| Hirmerová J, [Scaron]ubrt I, [Scaron]lechtová J, Hess Z |
| |
|
Clinical and Laboratory Studies of 25 Patients with von Willebrand Disease in Taiwan
|
| Chen Y-C, Cheng S-N, Chao T-Y, Tsai W-T, Liang W-C, Chiang J-L |
| |
|
Clinical and Molecular Characterization of Three Italian Patients with Severe Factor V Deficiency and Bleeding Disorder (‘Parahaemophilia’): Report of a Novel Homozygous Mutation (FV: Asp524His)
|
| Tognin G, Rossetto V, Barillari G, Gavasso S, Zerbinati P, Pagnan A, Simioni P |
| |
|
Clinical and Pharmacoeconomic Impact of Secondary Prophylaxis in Young-Adults with Severe Hemophilia A
|
| Coppola A, Cimino E, Macarone Palmieri N, De Simone C, Tufano A, Lombardini D, Albisinni R, Cerbone AM, Di Minno G |
| |
|
Clinical Application of the Clot Formation and Lysis (ClofAL) Assay to Physiologic and Pathologic Changes in Factor VIII
|
| Goldenberg NA, Jacobson L, Hathaway WE |
| |
|
Clinical Audit of Thromboembolism Prophylaxis 3 years after the 6th ACCP Report in a Tertiary Care Hospital in Córdoba, Argentina
|
| Tabares AH, Ballarino GJ, Benegas M, Cremona LS, Casanegra AI |
| |
|
Clinical Course and Management of 7 Patients with Congenital Factor XIII Deficiency. Experience of a Single Institution
|
| Garcia-Talavera J, Tarin F, Marrero C, León A, Trujillo M, Bello T, Jover S, Herrera M, Mesa M, Rios P, Hernanz P, Breña J |
| |
|
Clinical Efficacy and Safety Evaluation of ADVATE Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHF-PFM) During Surgical and Invasive Procedures
|
| Négrier C, Shapiro A, Pabinger I, Berntorp E, Tarantino M, Retzios A, Fritsch S, Luu H, Ewenstein B |
| |
|
Clinical Efficacy and Safety of Wilate, a Novel, High-purity VWF/FVIII-Concentrate with Optimized Pharmacokinetic Properties in the Treatment of von Willebrand Disease
|
| Windyga J, Zarkova A, Walter O, Auerswald G |
| |
|
Clinical Evaluation of a New Functional Test for Detection of Activated Protein C Resistance (Pefakit® APC-R Factor V Leiden) at Two Centers in Europe and the USA
|
| Schöni R, Quehenberger P, Wu J, Wilmer M |
| |
|
Clinical Evaluation of Thromboembolic Samples with the New HemosIL™ D-Dimer HS and the HemosIL™ D-Dimer Assays on the ACL TOP
|
| Morelli B, Stefanin C, Sales M, Arza B, Spagnotto M |
| |
|
Clinical Experience with Nadroparin in Pediatric Patients with Venous Thrombosis
|
| van Ommen CH, Peters M |
| |
|
Clinical Experience with Optional Vena Cava Filters: Results of a Prospective Observational Multicenter Study
|
| Imberti D, Bianchi M, Farina A, Siragusa S, Silingardi M, Ageno W |
| |
|
Clinical Experience with Retrievable ALN Vena Cava Filters
|
| Mismetti P, Rivron-Guillot K, Quenet S, Decousus H, Laporte S, Barral FG |
| |
|
Clinical Features and HIT Frequencies in Patient Subgroups
|
| Warkentin TE |
| |
|
Clinical Features of Cerebral Venous Thrombosis
|
| Schliamser L, Mahagney A, Weller B, Attias D |
| |
|
Clinical Hemorheology in Cardiovascular Surgery
|
| Roitman EV |
| |
|
Clinical History, Risk Factors, and Use of VTE Prophylaxis in Patients with Symptomatic DVT in China
|
| Turpie AGG |
| |
|
Clinical Impact of Screening for Factor V Leiden First Degree Relatives of Patients with an Acute Episode of VTE in Association with Factor V Leiden
|
| Couturaud F, Lacut K, Le Gall G, Oger E, Descourt R, Gutgobert C, Abgrall JF, Treguer G, Blouch MT, Leroyer C, Mercier B, Ferec C, Mottier D |
| |
|
Clinical Implications of Individual Time Within Target Range (ITTR) in Patients with Atrial Fibrillation (AF) treated with Vitamin K Antagonists
|
| Veeger NJGM, Hillege HL, Piersma-Wichers M, van der Meer J |
| |
|
Clinical Importance of Measurement of Soluble Fibrin Monomer-Fibrinogen Complex in Patients with Disseminated Intravascular Coagulation Syndrome and Hypercoagulable State
|
| Koga S, Tamimoto S, Nakahara K, Sakurai G, Matsuda M, Nakakuma H |
| |
|
Clinical Management Study of Venous Thromboembolism (VTE) Using the HemosIL™ D-Dimer
|
| Arnout J, Sales M, ArzaSánchez BT, Serra J, de Moerloose P |
| |
|
Clinical Manifestations of Patients with Dysfibrinogenemia
|
| Miesbach W, Catania V, Böhm M, Scharrer I |
| |
|
Clinical Measurements of Platelet Activation by Flow Cytometry Under Optimised Conditions
|
| Jennings GM, Phillips S, Ralis H, Davies DA, Chatamra K, Giddings JC |
| |
|
Clinical Phenotype of Hemophilia and Prothrombotic Gene Mutation
|
| Hlusi A, Krcova V, Novak P, Slavik L, Divoka M |
| |
|
Clinical Profile of Glanzmann's Thrombasthenia from the Sultanate of Oman
|
| Pathare AV, Al Kindi S, Zadjali S, Al Haddabi H, Al Abri QN, Gravell D, Al Lamki Z, Khanduri U, Dennison D |
| |
|
Clinical Relevance of Expression of VEGF-C and Its Receptors in Patients with Chronic Myelogenous Leukemia
|
| Ding K, Bai X, Hu X, Ruan C |
| |
|
Clinical Relevance of Expression of VEGF-C and Its Receptors IN Patients with Chronic Myelogenous Leukemia
|
| Ding K, Bai X, Hu X, Ruan C |
| |
|
Clinical Significance o IgG and IgM Anti-Phospholipid (aPL), Anti-Beta2-Glycoprotein I (aBeta2GPI), and Anti-Prothrombin (aPT) Antibodies: Retrospective and Prospective Analysis of the WAPS Study
|
| Galli M, Borrelli G, Finazzi G, Marfisi RM, Marchioli R, Marziali S, Barbui T |
| |
|
Clinical Significance of Antiphospholipid Antibodies in Haemophiliacs
|
| Miesbach W, Asmelash G, Putz B, Scharrer I |
| |
|
Clinical Use of Protamine for the Emergency Reversal of Anticoagulation with Low Molecular Weight Heparin (LMWH)
|
| van Veen JJ, Laidlaw S, Maclean RM, Hampton KK, Makris M |
| |
|
Clinical Usefulness of D-Dimer Depending on Clinical Probability and Cut-Off Value in Outpatients with Suspected Pulmonary Embolism
|
| Righini M, Aujesky D, Roy PM, Cornuz J, de Moerloose Ph, Bounameaux H, Perrier A |
| |
|
Clinical Usefulness of Prothrombin Fragment 1+2 in Patients with Suspected Pulmonary Embolism
|
| Sohne M, Meijers JCM, ten Wolde M, van Dongen CJ, Buller HR |
| |
|
Cloning Strategy and Humanization of the Potent Antithrombotic Agent 6B4, an Anti-Glycoprotein Ib Monoclonal Antibody
|
| Fontayne A, Vanhoorelbeke K, Pareyn I, Cauwenberghs N, Ngo TH, Dejaeghere D, La Roche Y, Deckmyn H |
| |
|
Clopidogrel Effect on Platelet Reactivity in Patients with Stent Thrombosis: Results of the CREST Study
|
| Gurbel PA, Bliden KP, Fissha M, Kevin Hayes K, Yoho J, Kreutz R, Tantry U |
| |
|
Closure Times Determined with a Platelet Function Analyzer are Closely Correlated to the Mean Transvalvular Gradient in Patients with Aortic-Valve Stenosis
|
| Sucker C, Kurt M, Feindt P, Zotz RB, Scharf RE |
| |
|
Clotting Factor Prophylaxis in Boys with Haemophilia; Experience from a Single Australian Centre
|
| Barnes C, Szentandrassy J, Speller T, Egan B, Ekert H, Monagle P |
| |
|
Clotting Profile by Sonoclot Analysis Is Different in Patients Undergoing Off-Pump and On-Pump Coronary-Artery Bypass Surgery
|
| Paniccia R, Caciolli S, Palmarini MFG, Beconcini S, Tellini I, Pretelli P, Stefano PL, Abbate R, Gensini GF, Prisco D |
| |
|
Clotting Time and Fibrinogen Concentration
|
| Savushkin AV |
| |
|
Clustering of Adipokines and Haemostatic Factors: Evidence for Transcriptional Co-regulation
|
| Carter AM, Bostock JA, McCormack LJ, Knight B, Prasad UK, Freeman MS, Grant PJ |
| |
|
Clusters of Ligand-Binding Domains of Low-density Lipoprotein Receptor-related Protein Bind both Heavy and Light Chain of Activated Factor V and Inhibit Cofactor Function
|
| Bos MHA, Boertjes RC, van der Zwaan C, Mertens K, Meijer AB |
| |
|
Coagucheck aPTT versus Central Laboratory aPTT for Anticoagulation Management after Cardiopulmonary Bypass
|
| Reber G, Merlani P, Chenaud C, Cottini S, Diby M, Ricou B, de Moerloose P |
| |
|
CoaguChek S Accuracy And Reproducibility in Comparison with the BCS Analyzer: Results in an Outpatient Anticoagulation Clinic
|
| Tsoukala C, Kotsi P, Anastasopoulou I, Gavalaki M, Kanellopoulou G, Adraktas, Th, Karafoulidou A |
| |
|
Coagulation Activation in Women with Hyperemesis Gravidarum
|
| Cole K, Ford I, Greaves M, Watson HG |
| |
|
Coagulation and Anticoagulan Factors in Combined Action of Informational Overload and Weak Static Magnetic Field
|
| Serebryakova T, Podorolskaya L, Nikolskaya K, Kovaleva V |
| |
|
Coagulation Defects in Thai Adolescents with Menorrhagia
|
| Sakara H, Ampaiwan C, Sukanya C, Anucha T, Saranya R |
| |
|
Coagulation Disorders in Severe leptospirosis in Indonesia
|
| Wagenaar JFP, Mairuhu ATA, Vught M, Heiden van der Y, Goris M, Sakundarno AM, Gasem MH, Gorp van ECM |
| |
|
Coagulation Factor X Deficiency Caused by a Mutant Signal Peptide that Affects Translocation to the Endoplasmic Reticulum
|
| Wang WB, Fu QH, Wang XF, Wang HL |
| |
|
Coagulation Factor XII is Essential for Arterial Thrombus Formation in Vivo
|
| Renné T, Pozgajová M, Grüner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B |
| |
|
Coagulation Factors VIIa and Xa Promote Apoptosis in Human Tumor Cells in Association with CREB Activation
|
| Borensztajn KS, Bijlsma MF, Versteeg HH, Bruggeman LW, Reitsma PH, Peppelenbosch MP, Spek CA |
| |
|
Coagulation in Aviation: Activation of the Coagulation System During Air Travel (The WRIGHT Volunteers Study)
|
| Schreijer AJM, Kuipers S, Cannegieter SC, Meijers JCM, Middeldorp S, Rosendaal FR, Büller HR |
| |
|
Coagulation Markers as Predictors of Disease Progression in Cancer
|
| Sitalakshmi S, Kumar KR, Damodar P |
| |
|
Coagulation Screening for Otorhinolaryngoiatric Surgery: A Pharmacoeconomic Appraisal in the Setting of the Italian National Health System
|
| Ferrante F, Fattorini L, Bifarini B, Tesoro S, Depunzio I, Peduto VA, Iorio A |
| |
|
Cobra Cardiotoxins, Members of the Ly-6 Protein Family, Specifically Bind to Integrin alphavbeta3
|
| Wu PL, Mori S, Lee SC, Akakura N, Wu WG, Takada Y |
| |
|
Cocoa Beverage Shows Platelet Inhibition Activity, Depressing Platelet Activation Antigens CD61, CD62p and PAC1 and Extending the PFA 100 Closure Time
|
| Naidu K, Farren T, Manari A, Howard I, Royle E, O'Shaughnessy D |
| |
|
Cofactor Binding – Dependent Hydrogen Bond Formation between Antithrombin III Strand 3A Tyrosine-220 and Strand 5A Glutamic Acid 374 Is Necessary for Backwards Conformational Adjustments Leading to Fully Developed Ionic Interactions between the Pentasaccharide and ATIII, and for Stabilization of High Affinity Heparin Binding
|
| Jairajpuri MA, Lu A, Olson ST, Bock SC |
| |
|
Cofactor-induced Zymogen Activation
|
| Bode W |
| |
|
Collagen Binding (VWF : CB) Is Less Sensitive Than Ristocetin Cofactor Activity (VWF : RCo) in Suggesting Von Willebrand Factor (VWF) Molecular Defects in Patients with Von Willebrand Disease Type 1: Results From the European Multicenter MCMDM-1VWD Study
|
| Federici AB, Canciani M, Goodeve A, Tosetto A, Budde U, Eikenboom JCJ, Peake I, Rodeghiero F, Castaman G, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F |
| |
|
Collagen-Induced Platelet Shape Change Does Not Require Positive Feedback Activators and Is Insensitive to cAMP Elevating Agents
|
| Riondino S, Lotti LV, Cutini C, Bronzi C, Pulcinelli FM |
| |
|
Combination of Loss of Function of Recombinant R1334A-VWF and Gain of Function of R1336A-VWF Results in a Loss of Function of RKR1334-1335-1336A-VWF
|
| Rastegar lari G, Vanhoorelbeke K, Martin K, Legendre P, Deckmyn H, Baruch D |
| |
|
Combinatorial Peptides Directed to Inhibitory Antibodies against Human Blood Clotting Factor VIII
|
| Kopecky E-M, Pabinger I, Greinstetter S, Buchacher A, Römisch J, Jungbauer A |
| |
|
Combined Deficiency of Factor V and Factor VIII: Compound Heterozygosity For Two Novel Truncating Mutations in ERGIC53/LMAN1
|
| Farah RA, de Moerloose P, Barakat W, Sayad AE, Neerman-Arbez M |
| |
|
Combined Genetic Risk Factors in Thrombophilic Serbian Population
|
| Djordjevic V, Rakicevic LJ, Miljic P, Mikovic D, Kovac M, Radojkovic D |
| |
|
Combined Oral Anticoagulant and Antiplatelet Therapy And Bleeding Risk
|
| Poli D, Antonucci E, Cecchi E, Ilari I, Alessandrello Liotta A, Lapini I, Cellai AP, Gensini GF, Abbate R, Prisco D |
| |
|
Combined Type 1 and Type 2N von Willebrand Disease: Contribution of Real Time PCR in Genotype Study
|
| Rugeri L, Dargaud Y, Arnuti B, Negrier C, Vinciguerra C |
| |
|
Combining Pretest Probability Score and Antigenic Assays in the Diagnosis of HIT – A Viable Alternative to Functional Assays
|
| Austin S, Low J, Shorey N, Johnston A, Joseph J |
| |
|
Common Factor XIII Gene Polymorphisms in Venous Leg Ulcers
|
| Gemmati D, Tognazzo S, Serino ML, Catozzi L, De Mattei M, Izzo M, Mazza P, Carandina S, De Palma M, Fogato L, Fortini P, Legnaro A, Palazzo A, Pancaldi F, Scapoli GL, Liboni A, Zamboni P |
| |
|
Comparative Analysis of Methods for Assessment of Circulating Endothelial Progenitor Cells Indicated Heterogeneity of Subpopulations at Various Stages of Differentiation
|
| Deutsch V, Shmilovich H, Abashidze A, Miller H, Keren G, Katz B, George J |
| |
|
Comparative Analysis of the APC Resistance in East Siberian Residences
|
| Matvienko AS, Bogdanov IG, Miromanova NA, Vitkovsky Yu A |
| |
|
Comparative Anticoagulant Effects of a Synthetic, Dual Antithrombotic/Antiplatelet Agent, CanAm 208, with Argatroban and Angiomax
|
| Iqbal O, Fareed J, Hoppensteadt D, Walenga J, Cunanan J, Fareed D, Daikur J, Haque W |
| |
|
Comparative Antiplatelet Effects of the Active Metabolites of CS-747 (Prasugrel, LY640315) and Clopidogrel
|
| Jakubowski JA, Sugidachi A, Ogawa T, Isobe T, Shimoji T, Suzuki N, Asai F |
| |
|
Comparative Antithrombotic Effects of an Ultra Low Molecular Wight Heparin (Oligo H) and Enoxaparin in Animal Models of Arterial Thrombosis
|
| Fareed J, Kaiser B, Ma Q, Hoppensteadt D, Maddineni J, Wahi R |
| |
|
Comparative Effects of a Contraceptive Vaginal Ring Delivering Nestorone® and Ethinyl Estradiol, and a Combined Oral Contraceptive Containing Levonorgestrel on Risk of Venous Thromboembolism Evaluated through Haemostasis Variables and Sex Hormone Binding Globulin
|
| Rad M, Kluft C, Sitruk-Ware R, de Kam ML, Meijer P, Sivin I, Menard J, Burggraaf J |
| |
|
Comparative Effects of a Contraceptive Vaginal Ring Delivering Nestorone® and Ethinyl Estradiol, and a Combined Oral Contraceptive Containing Levonorgestrel, on Lipids and Inflammation Markers of Arterial Disease
|
| Rad M, Sitruk-Ware R, Kluft C, de Kam ML, Sivin I, Menard J, Burggraaf J |
| |
|
Comparative Effects of Nitroxil (HNO) and NO on Platelet Function and Tyrosine Phosphorilation Pattern of Activated Human Platelets
|
| Bermejo E, Alberto MF, Saenz DA, Gamberalle1 R, Bari S, Rosenstein R, Lazzari MA |
| |
|
Comparative Evaluation of FXIIIA and P-selectin Expression on the Surface of Thrombin-activated Platelets and Microparticles
|
| Nagy Jr B, Hevessy Z, Katona E, Polgar J, Kappelmayer J |
| |
|
Comparative Investigation of Prothrombin Complex Concentrates: Differences in Levels of Markers Indicating Activation of Coagulation
|
| Lutze G, Heim M |
| |
|
Comparative Structural Analysis of Recombinant Factor VIII (rFVIII): Defining Full-Length FVIII
|
| Jankowski M, Weston S, Patel H, Sharpe P, Rouse J, Marzilli L |
| |
|
Comparative Study of Fibrinolysis Test Systems with A Special Focus on Variable Sample Handling (Different Transport Modalities/Arterial and Venous Catheterization)
|
| Strasser EF, Kriegbaum B, Menke D, Bittdorf B, Ringwald J, Zimmermann R, Weisbach V, Eckstein R |
| |
|
Comparative Study on the Anticoagulant Effects of Low Molecular Weight Heparins As Measured by Whole Blood ACT, Anti-Xa and a Newly Developed Prothrombinase Induced Clotting Time (PiCT) Assay
|
| Tobu M, Wahi R, Iqbal O, Hoppensteadt D, Walenga JM, Wilmer M, Fareed J |
| |
|
Comparing Bleed Frequency and Factor Concentrate Use Between Haemophilia A and Haemophilia B
|
| Pai KM, Walker I, Almonte T, Chan AK, Sek J, Decker K |
| |
|
Comparing Subcutaneous Low Molecular Weight Heparin (Dalteparin) Versus Intravenous Unfractionated Heparin in the Treatment of Acute Sub-massive Pulmonary Embolism: An Open Randomised Trial
|
| Tran HAM, Ting S, Gan TE |
| |
|
Comparison Among the New Immunoassays with Monoclonal Antibody Calibration and Home-Made Methods for Testing the Antiphospholipid Antibody (APA) Family
|
| Forastiero R, Adamczuk Y, Iglesias Varela ML, Cerrato G, Martinuzzo M |
| |
|
Comparison between Two Computer Algorithms in Oral Anticoagulant Dosage – A Doubleblind Randomised Controlled Trial
|
| Van Leeuwen Y, Rombouts EK, Kruithof CJ, Van Der Meer FJM, Rosendaal FR |
| |
|
Comparison of Activated Platelets with Platelet-derived Microparticles in Procoagulant Activity
|
| Kireev D, Popenko N, Sinauridze E, Pichugin A, Ataullakhanov F |
| |
|
Comparison of B-Cell Epitope and Mutation Type in Haemophilia A Patients
|
| Albert T, Oldenburg J, Graw J, Schramm W, Brackmann HH, Schwaab R |
| |
|
Comparison of Coaguchek S INRa with Hospital Laboratory Citrated Plasma INRs – What Is the Truth?
|
| Kitchen DP, Murray ET, Jennings I, Kitchen S, Woods TAL, Walker ID, Preston FE, Fitzmaurice DA |
| |
|
Comparison of Continuous and Subsampling Determination of Thrombin Generation in the Presence of Anticoagulants
|
| Lau A, Berry LR, Chan AKC |
| |
|
Comparison of Continuous and Subsampling Methods for Analysis of Thrombin Generation
|
| Lau A, Berry LR, Mitchell LG, Chan AKC |
| |
|
Comparison of Four D-Dimer Tests Combined with Clinical Probability Assessment to Exclude Deep Venous Thrombosis in Symptomatic Outpatients
|
| Low J, Joseph J, Samarasinghe I, Shorey N, Javen D, McGrath M |
| |
|
Comparison of Global Risk of Fatal Cardiovascular Disease in Three European Populations Using SCORE Equations: Results from the IMMIDIET Project
|
| Castelnuovo AD, Zito F, de Gaetano G, Arnout J, Cappuccio FP, Van Dongen MC, de Lorgeril M, Dirckx C, Donati MB, Krogh V, Siani A, Iacoviello L |
| |
|
Comparison of Ivy Bleeding Time (BT) and PFA-100 Closure Time (CT) in Hospitalised Patients
|
| Lokar L, Urlep-[Scaron]alinovic[cacute] V |
| |
|
Comparison of Platelet Deposition on Collagen in Cone-And-Plate and Parallel Plate Flow Chambers
|
| Szarvas M, Vereb G, Udvardy ML, Oparaugo P, Tóth J, Szántó T, Hársfalvi J |
| |
|
Comparison of Protein Profile Analysis in Patients with and without a History of Venous Thromboembolism: A Pilot Study
|
| Wichers IM, Gast MCW, Beijnen JH, Reitsma PH, Zwinderman AH, Brandjes DP, Meijers JCM, Büller HR, Middeldorp S |
| |
|
Comparison of the Anticoagulant Effects of Melagatran and LMWH in an Acquired Antithrombin Deficiency in Children with ALL Treated with L-Asparaginase: An Ex Vivo Study
|
| Kuhle S, Mitchell LG, Vegh P, Lau A |
| |
|
Comparison of the Anticoagulant Properties of BAY 59-7939 – An Oral, Direct Factor Xa Inhibitor – with Fondaparinux and Enoxaparin
|
| Hoppensteadt D, Neville B, Cunanan J, Maddenini J, Perzborn E, Misselwitz F, Fareed J |
| |
|
Comparison of the Effectiveness of Protamine Sulphate and Polybrene in Neutralising Heparin in Patient Samples for Laboratory Testing
|
| Just S, Kennedy G, Freeman R |
| |
|
Comparison of the Procoagulant Activity of T-Lymphoblastoid Cells with Fresh Platelets in Three Phospholipid Dependent Assays
|
| Pickering W, Gray E, Goodall AH, Barrowcliffe TW |
| |
|
Comparison of the Role of Protein Kinase C (PKC) in Platelet Spreading on Fibrinogen and Collagen Related Peptide (CRP)
|
| Thornber K, McCarty OJT, Watson SP, Pears CJ |
| |
|
Complement Activation on the Surface of Cell-Derived Microparticles in Rheumatoid Arthritis
|
| Biró É, Nieuwland R, Pronk LM, Sturk A, Tak PP, Hack CE |
| |
|
Complement Component C5a Predicts Future Cardiovascular Events in Patients with Advanced Atherosclerosis
|
| Kastl SP, Speidl WS, Exner M, Amighi J, Wagner O, Huber K, Minar E, Wojta J, Schillinger M |
| |
|
Complementary Antithrombotic Effects of Aspirin and Clopidogrel Based on PlA1/A2 Glycoprotein IIIa Polymorphism
|
| Dropinski J, Sanak M, Wegrzyn W, Dyszkiewicz-Korpanty A, Brzezinska-Kolarz B, Musial J, Szczeklik A |
| |
|
Complete Subunit Sequences and Glycan Structures of Factor X Activator from Russell's Viper Venom
|
| Chen HS, Chen CM, Lin CW, Khoo KH, Wang YM, Tsai IH |
| |
|
Complete Thrombolysis of Bilateral Pulmonary Embolism by Two-Sided Catheter-Directed Low-Dose Infusion of Tissue Plasminogen Activator
|
| Cannizzaro V, Berger F, Knirsch W, Albisetti M |
| |
|
Composite Islet-Endothelial Cell Grafts: A Novel Approach to Counteract Innate Immunity in Islet Transplantation
|
| Johansson U, Nilsson B, Korsgren O |
| |
|
Computer Simulation Model of Spatial Dynamics of Fibrin Clot Growth Under Conditions of Blood Flow
|
| Lobanova ES, Shibeko AM, Panteleev MA, Ataullakhanov FI |
| |
|
Concentration of TAFI and D-Dimers in Radically Operated Non-Small Cell Lung Cancer Patients
|
| Dworakowska D, Kulwas A, Lapinski M, Tomaszewski D, Dworakowski R, Skokowski J, Zekanowska E, Rosc D, Czestochowska E |
| |
|
Concentration of TF and TFPI in Non-Small Cell Lung Cancer
|
| Dworakowska D, Kulwas A, Lapinski M, Tomaszewski D, Dworakowski R, Skokowski J, Zekanowska E, Rosc D, Czestochowska E |
| |
|
Concomitant Infusion of Low Doses of rFVIIa and FEIBA in Severe Hemophilia A Patients with an Inhibitor to Factor VIII Who Are Refractory to rFVIIa or FEIBA Has an Excellent Hemostatic Effect and Synergistically Enhances Thrombin Generation
|
| Martinowitz U, Livnat T, Zivelin A, Luboshitz J, Seligsohn U, Kenet G |
| |
|
Confirmation of the Pathogenic Role of Ig M and Ig A Anti Heparin-PF4 Antibodies in Patients with Heparin-Induced-Thrombocytopenia
|
| Tardy-Poncet B, Piot M, Rancon F, Tardy B, Reynaud J, Campos L, Decousus H |
| |
|
Confirmatory Evidence for the Presence and Functional Activity of a Phosphatidylserine Receptor (PSR) on Endothelial Cells
|
| Setty BNY, Gayen-Betal S |
| |
|
Conformational and Functional Changes in Antithrombin by Oxidation
|
| Hernández-Espinosa D, Cano H, Miñano A, Martínez C, González-Conejero R, Vicente V, Corral J |
| |
|
Congenital Aplasia of the Inferior Vena Cava Is a Major Risk Factor for Iliofemoral Deep Venous Thrombosis. A Prospective One-centre Study of 50 Cases
|
| Jørgensen M, Bækgaard N, Mantoni M |
| |
|
Congenital Deficiency of Factor XIII Caused by Two Missense Mutations in a Dutch Family
|
| Onland W, Böing A, Schaap M, Nieuwland R, Haasnoot K, Sturk A, Peters M |
| |
|
Congenital Platelet ADP Receptor (P2Y12) Deficiency: A Case Report
|
| Elliott MA, Nichols WL, Miller RS, Lokken TG, Pruthi RK, Owen WG, Heit JA |
| |
|
Congenital Prothrombotic Disorders in Children with Venous and Arterial Thrombosis
|
| Albisetti M, Waldvogel K, Cannizzaro V, Anagnostopoulos A, Balmer C, Schmugge M |
| |
|
Conjoint Analysis to Elicit Preferences on Anticoagulant Treatment in Patients Receiving Vitamin K Antagonists (VKA)
|
| Monzini M, Carpenedo M, Villa M, Mantovani L, Moia M |
| |
|
Consideration of HIT Antibody Isotype in Interpretation of the Serotonin Release Assay
|
| Prechel M, McDonald MK, Jeske WP, Drenth AF, Walenga JM |
| |
|
Consistent Manufacturing of 50 Consecutive Octaplex® 500 Lots: Biochemical Characteristics of a Prothrombin Complex Concentrate
|
| Hoffer L, Weimar V, Weinberger J, Roemisch J |
| |
|
Construction and Characterization of MA-T94H3 Derivatives, a TAFI Neutralizing Antibody
|
| Develter J, Gils A, Buelens K, Declerck PJ |
| |
|
Construction of a Phage Display Library of Human Fab Antibodies against Human Platelet Membrane Glycoprotein IIb/IIIa
|
| Cui Y, Dong N, Pang A, Bai X, Ruan C |
| |
|
Contortrostatin: A Potent Inhibitor of Cancer Growth and Angiogenesis
|
| Markland FS, Swenson S, Minea R, Costa F, Fujii G |
| |
|
Contrast Medium Attenuates Platelet Activation and Platelet-Leukocyte Cross-Talk
|
| Ji Q, Ghaly M, Daleskog M, Johansson M-C, Hjemdahl P, Tornvall P, Li N |
| |
|
Contribution of Thymidylate Synthase Enhancer Region (TSER) Polymorphism to Total Plasma Homocysteine Levels in Korean Patients with Recurrent Spontaneous Abortion
|
| Kim NK, Choi YK, Kang MS, Choi DH, An MO, Cha SH, Oh D |
| |
|
Contributions of Blood Cells to Adenine Nucleotide Metabolism
|
| Johnson A, Glenn JR, White AE, Heptinstall S |
| |
|
Controversy in VWD Diagnosis and Treatment: Issues for Women and VWD
|
| Kadir RA |
| |
|
Conversion of Platelets from a Pro-Aggregatory to Pro-Inflammatory Adhesive Phenotype: A Role for PAF in Spatial Neutrophil Activation on Thrombi
|
| Kulkarni S, Woollard KJ, Thomas S, Kanagasundaram V, Jackson SP |
| |
|
Correlation Between Compresive Ultrasonography and D Dimer Levels in Patients with Deep Venous Thrombosis
|
| Maneyro A, Ouviña S, Guidobono R, Palmer L |
| |
|
Correlation Between Selected cloTting Factors Parameters and Apoptosis of Peripheral T Lymphocytes in Non-Small Cell Lung Cancer
|
| Dworakowska D, Bryl E, Soroczynska M, Witkowski JM, Lapinski M, Tomaszewski D, Dworakowski R, Skokowski J, Czestochowska E |
| |
|
Correlation Between Thromboelastographic and Whole Blood Aggregometrical Aspirin-Resistance Values and Neurological Events in Ventricular-Assist Device (VAD) Patients
|
| Reynolds R, Pierson R, Sorensen E, Kallam S, Lavador M, Romar L, Porter A, Griffith B, Poston R |
| |
|
Correlation of Various Mutations and Polymorphisms with the Risk of Thrombosis in Children
|
| Komitopoulou A, Platokouki H, Kapsimali Z, Pergantou H, Adamtziki E, Aronis S |
| |
|
Co-segregation of the PROS1 Locus and Protein S Deficiency in Families having no Detectable Mutations in PROS1
|
| Lanke E, Johansson AM, Hillarp A, LethagenZöller SB, Dahlbäck B, Halldén C |
| |
|
Cost-Effectiveness of Different Treatment Regimens Consisting of NovoSeven® Versus FEIBA VH for the Home Treatment of Minor-to-Moderate Bleeds in Hemophilia Patients With Inhibitors in the United States: A Cost-of-Bleed Model
|
| Joshi AV, Mathew P, Gore T |
| |
|
Could Haemostasis in Haemophilia A Be Normalised by Factor VIII (FVIII) Concentrates at Levels below 1 IU/mL? Studies with Various Methods of Thrombin Generation
|
| McIntosh JH, Owens D, Lee CA, Raut S, Barrowcliffe TW |
| |
|
Cranial Epidural Bleeding in a Child with Congenital Afibrinogenaemia, Management and Long-Term-Prophylaxis with a Fibrinogen Concentrate
|
| Klarmann D, Martinez-Saguer I, Stoll H, Nachtrodt G, Class D, Ivaskevicius V, Oldenburg J, Kreuz W |
| |
|
C-Reactive Protein 3'UTR (+1444) C>T Polymorphism in Patients with Spontaneous Venous Thromboembolism
|
| Vormittag R, Funk M, Mannhalter C, Schönauer V, Vukovich T, Minar E, Bialonczyk C, Hirschl M, Pabinger I |
| |
|
C-Reactive Protein and Its Determinants in European Populations at Different Risk of Cardiovascular Disease: Results from the IMMIDIET Project
|
| Arcari A, Di Castelnuovo A, Zito F, de Curtis A, Arnout J, Cappuccio FP, Siani A, de Gaetano G, Donati MB, Iacoviello L |
| |
|
C-reactive Protein in Combination with Clinical Decision Rule and D-Dimer to Safely Rule out Pulmonary Embolism
|
| Sohne M, Kruip MJHA, van Dongen CJ, Leebeek FWG, Bossuyt P, Buller HR |
| |
|
C-reactive Protein Polymorphisms and Ischemic Stroke
|
| Ladenvall C, Jood K, Blomstrand C, Nilsson S, Jern C, Ladenvall P |
| |
|
Critical Role of the Age-Related Homeostasis Mechanism in Amelioration of Hemophilia B Leyden: Role of Growth Hormone and Signal Transduction Network
|
| Kurachi S, Isobe T, Huo J, Kurachi K |
| |
|
CRM+ Factor V Deficiency Arg2080Cys: A Model to Investigate Altered C2 Domain-Membrane Interaction
|
| Scanavini D, Lunghi B, Gemmati D, Canella A, Grandini A, Tognazzo D, Bernardi F |
| |
|
Cross Validation of the 2nd International Standard of Low Molecular Weight Heparin (IS 2003–01/608) in the Anti-Xa, Anti-Iia Heptest and PiCT Tests
|
| Hoppensteadt D, Jeske J, Fareed D, Iqbal O, Wilmer M, Walenga J, Fareed J |
| |
|
Cross-over Comparative Study of Tolerability, Pharmacokinetics and Efficacy of Two Forms of Porcine Factor VIII in the Canine Model of Hemophilia A
|
| Bergman GE, Lillicrap D, Robinson P |
| |
|
Cross-Species Pharmacologic Evaluation of Plasmin as a Direct-Acting Thrombolytic Agent: ex vivo Evaluation for Large Animal Model Development
|
| Landskroner K, Olson NC, Jesmok G |
| |
|
Crosstalk Between Integrins a2b1 and aIIbb3 during Platelet Activation
|
| Schoolmeester A, Lecut C, Jandrot-Perrus M, Vanhoorelbeke K, Van de Walle G, Heemskerk JWM, Hoylaerts MF, Deckmyn H |
| |
|
CRP as a Biochemical Wells Score? A Double Approach (D-Dimer Plus CRP) in the Diagnosis of Deep Vein Thrombosis – Data from the CARDIM Study
|
| Korte W, Huisman MV, Dempfle CE |
| |
|
CRP Induces Platelet-Endothelial Adhesion Under Flow
|
| Brill A, Yaron G, Dashevsky O, Dannenberg H, Varon D |
| |
|
Crucial Role of Glycoprotein VI in Thrombus Formation and Coagulation during Venous and Arterial Thrombosis
|
| Munnix ICA, Strehl A, Kuijpers MJE, Auger JM, van Zandvoort MAMJ, oude Egbrink MGA, Nieswandt B, Heemskerk JWM |
| |
|
Crystal Structure of Calcium- and Integrin-Binding Protein 1: Insights to a Novel Mechanism of Action
|
| Blamey CJ, Ceccarelli C, Bahnson BJ, Naik UP |
| |
|
Crystal Structure of CIB1, an Endogenous Inhibitor of Platelet Integrin aIIbb3 Activation: Delineation of a New Family of Calcium-Binding Proteins
|
| Gentry HR, Singer AU, Betts L, Yang C, Ferrara JD, Sondek J, Parise LV |
| |
|
CS-747 (Prasugrel, LY640315) Produces Potent and Sustained Platelet Inhibitory Effects in Dogs and Monkeys During Multiple Dosing That Are Enhanced by Co-administration of Aspirin
|
| Asai F, Ogawa T, Jakubowski JA, Nagasawa T, Shimoji T, Suzuki N, Sugidachi A |
| |
|
CS-747 (Prasugrel, LY640315), a Novel Antiplatelet Agent, Inhibits Arterial Thrombosis Through Selective Blockade of Platelet P2Y12 Receptors
|
| Niitsu Y, Sugidachi A, Hasegawa M, Otsuguro K, Nakanishi Y, Jakubowski JA, Asai F |
| |
|
C-Terminal Domain of Beta2-Glycoprotein I Is Involved in Binding to Apoer2'
|
| Van Lummel M, Derksen RHWM, Westein E, Lenting PJ, De Groot PG |
| |
|
C-terminal Heparin-Binding Peptide of Snake Venom VEGF Specifically Blocks VEGF-stimulated Endothelial Cell Proliferation
|
| Yamazaki Y, Tokunaga Y, Takani K, Morita T |
| |
|
Current Transfusion Practices in two Autonomous Regions in Spain: Castilla La Mancha and Extremadura. Results from the Spanish Critical Care Society Hemoderivatives Working Group
|
| Quintana M, Leal SR, Garcia de Lorenzo A |
| |
|
Cyclic AMP Protects Stem Cell (CD34+) Apoptosis
|
| Negrotto S, D'Atri LP, Pozner RG, Lazzari MA, Gomez RM, Schattner M |
| |
|
Cyclooxygenase-2 Regulates Intravascular Thrombosis Following Hypoxia-Induced Pulmonary Hypertension in Gene Disrupted Mice
|
|
| |
|
Cyclosporine Reduces the Platelet Inhibitory Effect of Clopidogrel in Cardiac Transplant Patients
|
| Meier D, Lau W, Koelling T, Carville D, Guyer K, Neer C, Bates E |
| |
|
Cys570Ser Mutation in the von Willebrand Factor Propeptide in Recessive von Willebrand Disease
|
| Lanke E, Kristoffersson AC, Philips M, Holmberg L, Lethagen S |
| |
|
Cysteine Mutations in the von Willebrand Factor D3 Domain Correlate with Multimerization Defects in Patients Previously Diagnosed with von Willebrand Disease Type 1 in Patients Entered in the European Multicentre Study MCMDM-1VWD
|
| Schneppenheim R, Budde U, Goodeve A, Hilbert L, Ribba A, Obser T, Oyen F, Peake I, Rodeghiero F, Castaman G, Federici A, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F |
| |
|
Cystic Fibrosis is a Significant Risk Factor for Recurrent Venous Thrombosis at a Pediatric Tertiary Care Hospital
|
| Raffini L, Raybaykar D, Blumenstein M, Manno C |
| |
